Recent advances in molecular analysis of skeletal dysplasia

Pediatrics International

Volumn 39, Issue 4, 1997, Pages 491-498

  Ozono, Keiichi ^a  

^a RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

Author keywords

Allelic; Fibroblast growth factor receptor; Molecular diagnosis; Mutation; Polymorphism

Indexed keywords

ALKALINE PHOSPHATASE; COLLAGEN; FIBROBLAST GROWTH FACTOR RECEPTOR; VITAMIN D RECEPTOR;

ACHONDROPLASIA; ALBERS SCHOENBERG DISEASE; BONE DYSPLASIA; CHONDRODYSPLASIA; GENE MUTATION; HUMAN; HYPOPHOSPHATASIA; MOLECULAR BIOLOGY; OSTEOSCLEROSIS; PRIORITY JOURNAL; RECEPTOR GENE; REVIEW; THANATOPHORIC DWARFISM;

COLLAGEN; GTP-BINDING PROTEINS; HUMANS; HYPOPHOSPHATASIA; OSTEOCHONDRODYSPLASIAS; POLYMORPHISM, GENETIC; RECEPTORS, FIBROBLAST GROWTH FACTOR; VITAMIN D DEFICIENCY;

EID: 0030803194     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.1997.tb03626.x     Document Type: Review

References (72)

1. Shiang R., Thompson LM, Zhu Y-Z et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 1994; 78: 335–42.
2. Rousseau F., Bonaventure J., Legeai-Mallet L. et al. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 1994; 371: 252–4.
3. Superti-Furga A., Eich G., Bucher HU et al. A glycine 375-to-cysteine substitution in the transmembrane domain of the transmembrane domain of the fibroblast growth factor receptor-3 in a newborn with achondroplasia. Eur. J. Pediatr. 1995; 154: 215–19.
4. Prinos P., Costa T., Sommer A., Kilpatrick MW, Tsipouras P. A common FGFR3 gene mutation in hypochondroplasia. Hum. Mol. Genet. 1995; 4: 2097–101.
5. Bellus GA, McIntosh I., Smith EA et al. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nature Genet. 1995; 10: 357–9.
6. Tavormina PL, Shiang R., Thompson LM et al. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nature Genet. 1995; 9: 321–8.
7. Rousseau F., Ghouzzi VE, Delezoide AL et al. Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1). Hum. Mol. Genet. 1996; 5: 509–512.
8. Tavormina PL, Rimon DL, Cohn DH, Zhu Y-Z, Shiang R., Wasmuth JJ. Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. Hum. Mol. Genet. 1995; 4: 2157–77.
9. Muenke M., Schell U., Hehr A. et al. A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome. Nature Genet. 1994; 8: 269–74.
10. Lajeunie E., Ma HW, Bonaventure J., Munnich A., Le Merrer M. FGFR2 mutations in Pfeiffer syndrome. Nature Genet. 1995; 9: 108.
11. Rutland P., Pulleyn LJ, Reardon W. et al. Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon syndrome phenotypes. Nature Genet. 1995; 9: 173–6.
12. Reardon W., Winter RM, Rutland P., Pulleyn LJ, Jones BM, Malcolm S. Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. Nature Genet. 1994; 8: 98–103.
13. Li X., Park W-J, Pyeritz RE, Jabs EW. Effect on splicing of a silent FGFR2 mutation in Crouzon syndrome. Nature Genet. 1995; 9: 232–3.
14. Wilkie AOM, Slaney SF, Oldridge M. et al. Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nature Genet. 1995; 9: 165–72.
15. Jabs EW, Li X., Scott AF et al. Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2. Nature Genet. 1994; 8: 275–9.
16. Meyers GA, Orlow SJ, Munro IR, Przylepa KA, Jabs EW. Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nature Genet. 1995; 11: 462–4.
17. Wilkie AOM, Slaney SF, Oldridge M. et al. Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nature Genet. 1995; 9: 165–72.
18. Przylepa KA, Paznekas W., Zhang M. et al. Fibroblast growth factor receptor 2 mutations in Beare-Stevenson cutis gyrata syndrome. Nature Genet. 1995; 13: 492–4.
19. Kuivaniemi H., Tromp G., Prockop DJ. Mutations in collagen genes: causes of rare and some common diseases in humans. FASEB J. 1991; 5: 2052–60.
20. Redford-Badwal DA, Stover ML, Valli M., McKinstry MB, Rowe DW. Nuclear retention of COLIA1 messenger RNA identifies null alleles causing mild osteogenesis imperfecta. J. Clin. Invest. 1996; 97: 1035–40.
21. Vissing H., D'Aleesio M., Lee B., Ramirez F., Godfrey M., Hollister DW. Glycine to serine substitution in the triple helical domain of Pro-αl(II) collagen results in a lethal perinatal form of short-limbed dwarfism. J. Biol. Chem. 1989; 264: 18 265–7.
22. Chan D., Taylor TKF, Cole WG. Characterization of an arginine 789 to cysteine substitution in αl(II) collagen chains of a patient with spondyloepiphyseal dysplasia. J. Biol. Chem. 1993; 268: 15238–45.
23. +51VS20) in the type II collagen gene (COL2AI) in a family with spondyloeiphyseal dysplasia congenita. Am. J. Hum. Genet. 1995; 56: 388–95.
24. Bogaert R., Wilkin D., Wilcox WR et al. Expression, in cartilage, of a 7-amino-acid deletion in type II collagen from two unrelated individuals with Kniest dysplasia. Am. J. Hum. Genet. 1994; 55: 1128–36.
25. Winterpacht A., Hubert M., Schwarze U., Mundlos S., Spranger J., Zabel BU. Kniest and Stickler dysplasia phenotypes caused by collagen type II gene (COL2A1) defect. Nature Genet. 1993; 3: 323–6.
26. Richards AJ, Yates JRW, Williams R. et al. A family with Stickler syndrome type 2 has a mutation in the COL11A1 gene resulting in the substitution of glycine 97 by valine in od(XI) collagen. Hum. Mol. Genet. 1996; 5: 1339–43.
27. Muragaki Y., Mariman ECM, Van Beersum SEC et al. A mutation in the gene encoding the α2 chain of the fibril-associated collagen IX COL9A2, causes multiple epiphyseal dysplasia (EDM2). Nature Genet. 1996; 12: 103–5.
28. Warman ML, Abbott M., Apte SS et al. A type X collagen mutation causes Schmid metaphyseal chondrodysplasia. Nature Genet. 1993; 5: 79–82.
29. Schipani E., Kruse K., Jüppner H. A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science 1995; 268: 98–100.
30. Weinstein LS, Shenker A., Gejman PV, Merino MJ, Friedman E., Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N. Engl. J. Med. 1991; 325: 1688–95.
31. sα gene. Hum. Mol. Genet. 1995; 4: 1675–6.
32. Patten JL, Johns DR, Valle D. et al. Mutations in the gene encoding the stimulatory G protein of adenylate cyclase in Albright's hereditary osteodystrophy. N. Engl. J. Med. 1990; 322: 1412–19.
33. sα gene (GNAS1) in patients with Albright hereditary osteodystrophy. Hum. Mol. Genet. 1995; 4: 2001–2.
34. Hughes MR, Malloy PJ, Kieback DG et al. Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets. Science 1988; 242: 1702–5.
35. Malloy PJ, Weisman Y., Feldman D. Hereditary 1α,25-dihydroxyvitamin D-resistant rickets resulting from a mutation in the vitamin D receptor deoxyribonucleic acid-binding domain. J. Clin. Endocrinol. Metab. 1994; 78: 313–16.
36. Whyte MP. Hypophosphatasia and the role of alkaline phosphatase in skeletal mineralization. Endocr. Rev. 1994; 15: 439–61.
37. Sly WS, Hewett-Emmett D., Whyte MP, et al. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc. Natl Acad. Sci. USA 1983; 80: 2752–6.
38. Gelb BD, Shi G-P, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996; 273: 1236–8.
39. Briggs MD, Hoffman SMG, King LM et al. Pseudoachondroplasia and multiple epiphyseal dysplasia due to mutations in the cartilage oligomeric matrix protein gene. Nature Genet. 1995; 10: 330–6.
40. Hecht JT, Nelson LD, Crowder E. et al. Mutations in exon 17B of cartilage oligomeric matrix protein (COMP) cause pseudoachondroplasia. Nature Genet. 1995; 10: 325–9.
41. Foster JW, Dominguez-Steglich MA, Guioli S. et al. Campomelic dysplasia and autosomal sex reversal caused by mutations in an SRY-related gene. Nature 1994; 372: 525–30.
42. Ninomiya S., Isomura M., Narahara K., Seino Y., Nakamura Y. Isolation of a testis-specific cDNA on chromosome 17q from a region adjacent to the breakpoint of t(12; 17) observed in a patient with acampomelic campomelic dysplasia and sex reversal. Hum. Mol. Genet. 1996; 5: 69–72.
43. Hästbacka J., De La Chapelle A., Mahtani MM et al. The diastrophic dysplasia gene encodes a novel sulfate transporter: Positional cloning by fine-structure linkage disequilibrium mapping. Cell 1994; 78: 1073–87.
44. Superti-Furga A. A defect in the metabolic activation of sulfate in a patient with achondrogenesis type 1B. Am. J. Hum. Genet. 1994; 55: 1137–45.
45. Hästbacka J., Superti-Furga A., Wilcox WR, Rimoin DL, Cohn DH, Lander ES. Atelosteogenesis type II is caused by mutations in the diastrophic dysplasia sulfate-transporter gene (DTDST): Evidence for a phenotypic series involving three chondrodysplasias. Am. J. Hum. Genet. 1996; 58: 255–62.
46. Jabs EW, Müller U., Li X. et al. A mutation in the homeodomain of the human MSX2 gene in a family affected with autosomal dominant craniosynostosis. Cell 1993; 75: 443–50.
47. Thomas JT, Lin K., Nandedkar M., Camargo M., Cervenka J., Luyten FP. A human chondrodysplasia due to a mutation in a TGF-ß superfamily member. Nature Genet. 1996; 12: 315–17.
48. Muenke M., Schell U. Fibroblast-growth-factor receptor mutations in human skeletal disorders. Trends Genet. 1995; 11: 308–13.
49. Sillence D. Osteogenesis imperfecta: an expanding panorama of variants. Clin. Orthop. Relat. Res. 1981; 159: 11–25.
50. Hayashi K. PCR-SSCP: A simple and sensitive method for detection of mutations in the genomic DNA. PCR Methods Appl. 1991; 1: 34–8.
51. Brow MAD, Oldenburg MC, Lyamichev V. et al. Differentiation of bacterial 16S rRNA genes and intergenic regions an Myobacterium tuberculosis KatG genes by structure-specific endonuclease cleavase. J. Clin. Microbiol. 1996; 34: 3129–37.
52. Bellus GA, Hefferon TW, De Luna RIO et al. Achondroplasia is defined by recurrent G380R mutations of FGFR3. Hum. Mol. Genet. 1995; 56: 368–73.
53. Bellus GA, Gaudenz K., Zackai EH et al. Identical mutations in three different fibroblast growth factor receptor genes in autosomal dominant craniosynostosis syndromes. Nature Genet. 1996; 14: 174–6.
54. Ma L., Golden S., Wu L., Maxson R. The molecular basis of Boston-type craniosynostosis: the Pro 148 His mutation in the N-terminal arm of the MSX2 homeodomain stabilizes DNA binding without altering nucleotide sequence preferences. Hum. Mol. Genet. 1996; 5: 1915–20.
55. Liu YH, Kundu R., Wu L. et al. Premature suture closure and ectopic cranial bone in mice expressing Msx2 transgenes in the developing skull. Proc. Natl Acad. Sci. USA 1995; 92: 6137–41.
56. Webster MK, Donoghue DJ. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J. 1996; 15: 520–7.
57. Galvin BD, Hart KC, Meyer AN, Webster MK, Donoghue DJ. Constitutive receptor activation by Crouzon syndrome mutations in fibroblast growth factor receptor (FGFR) 2 and FGFR2/Neu chimeras. Proc. Natl Acad. Sci. USA 1996; 93: 7894–9.
58. Naski MC, Wang Q., Xu J., Ornitz DM. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nature Genet. 1996; 13: 233–7.
59. Deng C., Wynshaw-Boris A., Zhou F., Kuo A., Leder P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 1996; 84: 911–21.
60. Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nature Genet. 1996; 12: 390–7.
61. Grant SFA, Reid DM, Blake G., Herd R., Fogelman I., Ralston SH. Reduced bone density and osteoporosis associated with a polymorphic Spl binding site in the collagen type α1 gene. Nature Genet. 1996; 14: 203–5.
62. Schwindinger WF, Francomano CA, Levine MA. Identification of a mutation in the gene encoding the a subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Proc. Natl Acad. Sci. USA 1992; 89: 5152–6.
63. Yamamoto T., Ozono K., Kasayama S. et al. Increased IL-6 production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome. J. Clin. Invest. 1996; 98: 30–5.
64. Vortkamp A., Lee K., Lanske B., Segre GV, Kronenberg HM, Tabin CJ. Regulation of rate of cartilage differentiation by indian hedgehog and PTH-related protein. Science 1996; 273: 613–22.
65. Labuda M., Morgan K., Glorieux FH. Mapping autosomal recessive vitamin D dependency type I to chromosome 12ql4 by linkage analysis. Am. J. Hum. Genet. 1990; 47: 28–36.
66. Yagi H., Ozono K., Miyake H., Nagashima K., Kuroume T., Pike JW. A new point mutation in the deoxyribonucleic acid binding domain of the vitamin D receptor in a kindred with hereditary 1,25-dihydroxyvitamin D-resistant rickets. J. Clin. Endocrinol. Metab. 1993; 76: 509–12.
67. Soriano P., Montgomery C., Geske R., Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991; 64: 693–702.
68. Hodgkinson CA, Moore KJ, Nakayama A. et al. Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel Basic-Helix-Loop-Helix-Zipper protein. Cell 1993; 74: 395–404.
69. Grigoriadis AE, Wang Z-Q, Cecchini MG et al. c-Fos: A key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994; 266: 443–8.
70. Tezuka K., Tezuka Y., Maejima A. et al. Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. J. Biol. Chem. 1994; 269: 1106–9.
71. Weiss MJ, Cole DEC, Ray K. et al. A missense mutation in the human liver/bone/kidney alkaline phosphatase gene causing a lethal form of hypophosphatasia. Proc. Natl Acad. Sci. USA. 1988; 85: 7666–9.
72. Ozono K., Yamagata M., Michigami T. et al. Identification of novel mutations (Phe310Leu and Gly439Arg) in a neonatal case of hypophosphatasia. J. Clin. Endocrinol. Metab. 1996; 81: 4458–61.